Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | CCND1 | P24385 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15066924 | 0.99 | ALK (0.41) | ALKSLC16A3CDK4CCND1ADRB1 | |
| SCHEMBL16674793 | 0.90 | ALK (0.42) | ALKSLC16A3MAOBCDK2HRH4 | |
| SCHEMBL15066754 | 0.89 | ALK (0.41) | ALKSLC16A3MAOBCDK2CDK7 | |
| SCHEMBL15066113 | 0.87 | CDK2 (0.41) | ALKSLC16A3CDK4CCND1MAOB | |
| Hydrochloric Acid SCHEMBL15066821 | 0.86 | CDK2 (0.41) | ALKSLC16A3CDK4CCND1MAOB | |
| SCHEMBL15066711 | 0.85 | CDK1 (0.40) | ALKSLC16A3CDK4CCND1ADRB1 | |
| Hydrochloric Acid SCHEMBL15066157 | 0.84 | CDK1 (0.40) | ALKSLC16A3CDK4CCND1ADRB1 | |
| SCHEMBL15066360 | 0.81 | ADRB1 (0.48) | ALKSLC16A3CDK4CCND1ADRB1 | |
| SCHEMBL15066175 | 0.81 | ALK (0.42) | ALKSLC16A3ADRB1MAOBHTR3E | |
| SCHEMBL15066288 | 0.81 | ALK (0.46) | ALKSLC16A3ADRB1MAOBCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | claimed |
| EP-2797592-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | claimed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | claimed |
| WO-2015095449-A1 | METHODS FOR MODULATING THE AMOUNT RNA TRANSCRIPTS | PTC THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | claimed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | claimed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | claimed |
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2797592-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2797592-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2015095449-A1 | METHODS FOR MODULATING THE AMOUNT RNA TRANSCRIPTS | PTC THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM17, RBM22 | ALK 4482/4885SLC16A3 4008/4885CDK4 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.